The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Open accessAbstract
BACKGROUND: Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential effects of that drug. METHODS: We sequenced the exons of NPC1L1 in 7364 patients with coronary heart disease and in 14,728 controls without such disease who were of European, African, or South Asian ancestry. We identified carriers of inactivating mutations (nonsense, splice-site, or frameshift mutations). In addition, we genotyped a specific inactivating mutation (p.Arg406X) in 22,590 patients with coronary heart disease and in 68,412 controls. We tested the association between the presence of an inactivating mutation and both plasma lipid levels and the risk of coronary heart disease. RESULTS: With sequencing, we identified 15 distinct NPC1L1 inactivating mutations; approximately 1 in every 650 persons was a heterozygous carrier for 1 of these mutations. Heterozygous carriers of NPC1L1 inactivating mutations had a mean LDL cholesterol level that was 12 mg per deciliter (0.31 mmol per liter) lower than that in noncarriers (P=0.04). Carrier status was associated with a relative reduction of 53% in the risk of coronary heart disease (odds ratio for carriers, 0.47; 95% confidence interval, 0.25 to 0.87; P=0.008). In total, only 11 of 29,954 patients with coronary heart disease had an inactivating mutation (carrier frequency, 0.04%) in contrast to 71 of 83,140 controls (carrier frequency, 0.09%). CONCLUSIONS: Naturally occurring mutations that disrupt NPC1L1 function were found to be associated with reduced plasma LDL cholesterol levels and a reduced risk of coronary heart disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A genetic sequencing study involving more than 90,000 patients found significantly lower LDL-C levels and a lower risk of coronary heart diseases among patients with NPC1L1 mutations [58]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Polymorphisms affecting NPC1L1 are associated with both lower levels of LDL cholesterol and a lower risk of cardiovascular events.19”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“There is no clear evidence that statins have a clinically significant beneficial or adverse effect on renal function [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“A systematic review of the benefits and harms of statins in patients with a functioning kidney transplant included 3465 patients, free of CHD, from 22 studies. Although the authors concluded that statins may reduce CV events, they also suggested a need for additional studies [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“A systematic review of the benefits and harms of statins in patients with a functioning kidney transplant included 3465 patients, free of CHD, from 22 studies. Although the authors concluded that statins may reduce CV events, they also suggested a need for additional studies [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“Naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [245]
In the citing paper
“Similarly, a lifelong reduction of only 11% in plasma LDL-cholesterol levels due to loss-of-function mutations in NPC1L1, an intestinal cholesterol transporter, causes a striking 53% reduction in myocardial infarction (37).”
From Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms (2018) · cites this paper as [37]
In the citing paper
“Naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD.245”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [245]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
Self-citationBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
(1989) · PubMed · Cited by 3,139
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G. G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,818
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J. R., Kwiterovich, P. O., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,645
Flagged first, then by citations
Research works printed but not linked: 2
- Taylor HA, 2005, Ethn Dis, 15, S6
- Ye Z, 2013, Glob Cardiol Sci Pract, 2013, 82
Cited by
Sorted by citations
Items 201–300 of 428
New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
Katzmann, J. L., & Laufs, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1159-z · Cited by 19
Jansen, H., Lieb, W., & Schunkert, H. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6640-y · Cited by 19
Khan, S. U., Saeed, S., Alsuhaibani, A. M., Fatima, S., Rehman, K. U., Zaman, U., Ullah, M., Refat, M. S. E.-D., & Lu, K. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101821 · Cited by 19
Muendlein, A., Leiherer, A., Saely, C. H., Rein, P., Zanolin, D., Kinz, E., Brandtner, E., Fraunberger, P., & Drexel, H. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.011 · Cited by 18
Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?
Santos, R. D. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000391 · Cited by 18
Otto, S., Lütjohann, D., Kerksiek, A., Friedrichs, S., Schulze, P. C., Möbius‐Winkler, S., Pörner, T. C., & Weingärtner, O. (2022) · Steroids · doi:10.1016/j.steroids.2022.109079 · Cited by 17
Gylling, H., Strandberg, T. E., Kovanen, P. T., & Simonen, P. P. (2020) · Nutrients · doi:10.3390/nu12082346 · Cited by 17
Bisphenol A promotes cholesterol absorption in Caco-2 cells by up-regulation of NPC1L1 expression
Feng, D., Zou, J., Zhang, S., Li, X., Li, P., & Lu, M. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-016-0395-0 · Cited by 17
Mazhar, F., & Haider, N. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.195906 · Cited by 16
Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention
Smith, B., Wright, C., & Davidson, M. H. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0550-5 · Cited by 16
The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.046 · Cited by 16
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17
Baila-Rueda, L., Pérez-Ruiz, M. R., Jarauta, E., Tejedor, M. T., Mateo‐Gállego, R., Lamíquiz-Moneo, I., de Castro-Orós, I., Cenarro, A., & Civeira, F. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.005 · Cited by 16
Statin Combination Therapy and Cardiovascular Risk Reduction
Toth, P. P., Farnier, M., Tomassini, J. E., Foody, J. M., & Tershakovec, A. M. (2016) · Future Cardiology · doi:10.2217/fca-2015-0011 · Cited by 17
McPherson, R., & Hegele, R. A. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.305012 · Cited by 15
The Application of the LDL Principle
Schade, D. S., Cavanaugh, B., Ramo, B. W., & Eaton, R. P. (2016) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2016.65012 · Cited by 15
Gomes, G. B., Zazula, A. D., Shigueoka, L., Fedato, R. A., da Costa, A. B. B. A., Guarita-Souza, L. C., Baena, C. P., Olandoski, M., & Faria‐Neto, J. R. (2017) · Journal of Medicinal Food · doi:10.1089/jmf.2016.0042 · Cited by 15
Human genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Mori, K., Ishida, T., Tsuda, S., Oshita, T., Shinohara, M., Hara, T., Irino, Y., Toh, R., & Hirata, K. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.32615 · Cited by 14
Glicksberg, B. S., Amadori, L., Akers, N. K., Sukhavasi, K., Franzén, O., Li, L., Belbin, G. M., Akers, K. L., Shameer, K., Badgeley, M. A., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0542-3 · Cited by 15
Musunuru, K., Arora, P. K., Cooke, J. P., Ferguson, J. F., Hershberger, R. E., Hickey, K. T., Lee, J., Lima, J. A. C., Loscalzo, J., Pereira, N. L., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000046 · Cited by 14
Novel genes in LDL metabolism – a comprehensive overview
Christoffersen, M., & Tybjærg‐Hansen, A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000175 · Cited by 16
Dimova, L. G., de Boer, J. F., Plantinga, J. A., Plösch, T., Hoekstra, M., Verkade, H. J., & Tietge, U. J. F. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.019 · Cited by 13
Genome-wide suppressor screen identifies USP35/USP38 as therapeutic candidates for ciliopathies
Tsai, I.-C., Adams, K. A., Tzeng, J. A., Shennib, O., Tan, P. L., & Katsanis, N. (2019) · JCI Insight · doi:10.1172/jci.insight.130516 · Cited by 14
Enas, E. A., & Dharmarajan, T. (2016) · Journal of Clinical and Preventive Cardiology · doi:10.4103/2250-3528.186499 · Cited by 13
Mapping Hyperlipidemia in Young Adulthood to Coronary Risk
Martin, S. S., & Michos, E. D. (2015) · Circulation · doi:10.1161/circulationaha.114.014433 · Cited by 13
Huang, Z., Tan, R., Meng, L., Yang, H., Liang, X., Qin, Y., & Luo, Z. (2019) · Journal of International Medical Research · doi:10.1177/0300060519862099 · Cited by 12
Rosenson, R. S., & Köenig, W. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6642-9 · Cited by 12
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Figorilli, F., Mannarino, M. R., Bianconi, V., & Pirro, M. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00529-2 · Cited by 12
Using human genetics to predict the effects and side-effects of drugs
Stender, S., & Tybjærg‐Hansen, A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000280 · Cited by 13
Bogsrud, M. P., Ulven, S. M., & Holven, K. B. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000299 · Cited by 12
Povsic, T. J., Scott, R. C., Mahaffey, K. W., Blaustein, R. O., Edelberg, J. M., Lefkowitz, M. P., Solomon, S. D., Fox, J. C., Healy, K. E., Khakoo, A. Y., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6739-9 · Cited by 12
Zhang, Y., & Karakikes, I. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.008 · Cited by 13
Liao, J., Yang, L., Zhou, L., Zhao, H., Qi, X., Cui, Y., & Ouyang, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.755469 · Cited by 11
Sugiyama, S., Jinnouchi, H., Hieshima, K., Kurinami, N., Suzuki, T., MIYAMOTO, F., Kajiwara, K., Matsui, K., & Jinnouchi, T. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0028-z · Cited by 11
Cholesterol metabolism in cardiac sarcoidosis
Simonen, P. P., Lehtonen, J. Y. A., Gylling, H., & Kupari, M. M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.018 · Cited by 11
Zhao, X.-Q., Phan, B. A. P., Davis, J., Isquith, D. A., Dowdy, A. A., Boltz, S., Neradilek, M. B., Monick, E. A., Brockenbrough, A., Frechette, E. E. H. S., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.013 · Cited by 11
Yamanashi, Y., Takada, T., & Suzuki, H. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00690 · Cited by 11
Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease
Zhao, X., Xu, J., Tang, X., Huang, K., Li, J., Liu, R., Jiang, L., Zhang, Y., Wang, D., Sun, K., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.704501 · Cited by 11
Management of Familial Hypercholesterolemia in Hong Kong
Hu, M., Hooper, A. J., BOCKXMEER, F. M. V., Watts, G. F., Chan, J. C. N., & Tomlinson, B. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34314 · Cited by 11
Williams, S. C. P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601663113 · Cited by 11
Genética de la cardiopatía isquémica: del conocimiento actual a las implicaciones clínicas
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.02.033 · Cited by 11
Lee, Y., Hong, N., Lee, C. J., Park, S., Lee, B., Soo, B., & Kang, E. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30409-6 · Cited by 11
LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Hewing, B., & Landmesser, U. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0610-z · Cited by 11
Human gain-of-function MC4R variants show signaling bias and protect against obesity
Lotta, L. A., Mokrosiński, J., Mendes de Oliveira, E., Li, C., Sj, S., Luan, J., Brouwers, B., Ayinampudi, V., Bowker, N., Kerrison, N. D., et al. (2020) · Yearbook of pediatric endocrinology · doi:10.1530/ey.17.11.3 · Cited by 10
Gene transfer and genome editing for familial hypercholesterolemia
Canepari, C., & Cantore, A. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140997 · Cited by 11
Ezetimibe enhances and stabilizes anticoagulant effect of warfarin
Hashikata, T., Yamaoka‐Tojo, M., Kakizaki, R., Nemoto, T., Fujiyoshi, K., Namba, S., Kitasato, L., Hashimoto, T., Ishii, S., Kameda, R., et al. (2016) · Heart and Vessels · doi:10.1007/s00380-016-0832-z · Cited by 10
Koopal, C., van der Graaf, Y., Asselbergs, F. W., Westerink, J., & Visseren, F. L. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.015 · Cited by 10
Pharmacogenetics in Cardiovascular Medicine
Weeke, P. E. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.04.002 · Cited by 10
2018 George Lyman Duff Memorial Lecture
McPherson, R. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311392 · Cited by 11
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00037-x · Cited by 14
Shared Genetic Aetiology of Coronary Artery Disease and Atherosclerotic Stroke—2015
Kessler, T., Erdmann, J., Dichgans, M., & Schunkert, H. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0498-5 · Cited by 9
Sinning, D., Leistner, D. M., & Landmesser, U. (2016) · Herz · doi:10.1007/s00059-016-4430-8 · Cited by 9
Common and rare genetic variants and risk of CHD
Swerdlow, D. I., & Humphries, S. E. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.209 · Cited by 9
Capra, M. E., Pederiva, C., Viggiano, C., Fabrizi, E., Banderali, G., & Biasucci, G. (2022) · Nutrients · doi:10.3390/nu14142817 · Cited by 9
The year in cardiology 2014: prevention
Backer, G. D., Kastelein, J. J. P., & Landmesser, U. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu482 · Cited by 9
Insights from population-based analyses of plasma lipids across the allele frequency spectrum
Peloso, G. M., & Natarajan, P. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.01.003 · Cited by 10
Poongavanam, V., Kongsted, J., & Wüstner, D. (2019) · ACS Omega · doi:10.1021/acsomega.9b01668 · Cited by 9
Desmarchelier, C., Wolff, E., Defoort, C., Nowicki, M., Morange, P., Alessi, M., Valéro, R., Nicolay, A., Lairon, D., & Borel, P. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000480 · Cited by 9
Zhao, X., Li, J., Tang, X., Liu, R., Xu, J., Xu, L., Jiang, L., Huang, K., Tian, J., Feng, X., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.229 · Cited by 9
Infrequent TRIB3 coding variants and coronary artery disease in type 2 diabetes
Prudente, S., Bailetti, D., Mendonça, C., Mannino, G. C., Fontana, A., Andreozzi, F., Hastings, T., Mercuri, L., Alberico, F., Basile, G., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.030 · Cited by 9
Zachrison, K. S., Levine, D. A., & Hayward, R. A. (2015) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2015-110170 · Cited by 9
Parini, P., Melhuish, T. A., Wotton, D., Larsson, L., Osman, A., Eriksson, M., & Pramfalk, C. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.867 · Cited by 9
Genetically determined intelligence and coronary artery disease risk
Li, L., Pang, S., Zeng, L., Güldener, U., & Schunkert, H. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01721-x · Cited by 9
Genetics of Coronary Atherosclerosis
Aragam, K. G., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00003-0 · Cited by 9
Statin–Ezetimibe Combination Therapy In Diabetic Individuals
Filippatos, T. D., & Elisaf, M. (2015) · Angiology · doi:10.1177/0003319715598887 · Cited by 9
Mutations inNPC1L1and Coronary Heart Disease
Weingärtner, O., Lütjohann, D., & Patel, S. B. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1500124 · Cited by 9
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Individualized lipid-lowering therapy to further reduce residual cardiovascular risk
Weingärtner, O., Lütjohann, D., Plösch, T., & Elsässer, A. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.05.016 · Cited by 8
Genetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 8
Anderson, T. J. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.03.019 · Cited by 8
Чурилин, М. И., Кононов, С. И., Luneva, Y. V., Казанов, В. А., Azarova, I. E., Klyosova, E. Y., Быканова, М. А., Пасчоалини, Г., Харченко, А. В., Zhabin, S. N., et al. (2020) · Russian Journal of Genetics · doi:10.1134/s1022795420020040 · Cited by 8
Yang, H., Guo, Y., Wang, S., Lin, K. C., Wang, Y., Hou, J., Cao, J., Cheng, Y., Cheng, F., Yun, S., et al. (2024) · Food Biophysics · doi:10.1007/s11483-024-09834-w · Cited by 7
Jeff, J. M., Peloso, G. M., & Do, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000277 · Cited by 7
Zhang, A.-M., Zhang, C., Song, Y., Zhao, P., Feng, Y., Wang, B., Li, Z., Liu, L., & Xia, X. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.10.007 · Cited by 7
Serum non-cholesterol sterols and cholesterol metabolism in childhood and adolescence
Gylling, H., Korhonen, M., Mutanen, A., Nissinen, M. J., Pakarinen, M. P., & Simonen, P. P. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.017 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Eid, W., Sapp, E. H., Flerlage, E., & Nolan, J. R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.020800 · Cited by 7
Grassi, G. M., Pinto, R. D., Rosei, C. A., Agnoletti, D., Borghi, C., Cicero, A. F. G., Ciuceis, C. D., Desideri, G., Grassi, D., Muiesan, M. L., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00501-6 · Cited by 8
Jensen, J. S., Weeke, P. E., Bang, L. E., Høfsten, D. E., Ripa, M. S., Schjerning, A.-M., Theilade, J., Køber, L., Gislason, G., & Pallisgaard, J. L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022702 · Cited by 7
Are plant sterols and plant stanols a viable future treatment for dyslipidemia?
Gylling, H., & Simonen, P. P. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1166956 · Cited by 7
Hyperlipidemia and cardiovascular disease
Burkhardt, R. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000221 · Cited by 7
The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?
Khera, A. V., Natarajan, P., & Kathiresan, S. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315600818 · Cited by 6
Transcriptional regulation of Niemann-Pick C1-like 1 gene by liver receptor homolog-1
Lee, E. S., Seo, H. J., Back, S. S., Han, S. H., Jeong, Y. J., Lee, J. W., Choi, S. Y., & Han, K. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.9.253 · Cited by 6
Rare Diseases Related with Lipoprotein Metabolism
Zhou, H., Gong, Y., Wu, Q., Ye, X., Yu, B., Lu, C., Jiang, W., Ye, J., & Fu, Z. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6082-8_11 · Cited by 6
Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe
Schweitzer, M., Makhoul, S., Paliouras, M., Beitel, L. K., Gottlieb, B., Trifiro, M. A., Chowdhury, S. F., Zaman, N., Wang, E., Davis, H. R., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.032 · Cited by 6
Mechanisms of Niemann-Pick type C1 Like 1 protein degradation in intestinal epithelial cells
Malhotra, P., Soni, V. K., Yamanashi, Y., Takada, T., Suzuki, H., Gill, R. K., Saksena, S., Dudeja, P. K., & Alrefai, W. A. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00465.2018 · Cited by 6
Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
Lechner, K., Kessler, T., & Schunkert, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01408-9 · Cited by 6
Pharmacogenetics in Cardiovascular Diseases
Cavallari, L. H., & Momary, K. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00006-1 · Cited by 6
Aslani, S., Eslami, M. M., Fakourizad, G., Faiz, A. F., Mohammadi, K., Dehghan, O., Imani, D., Abbaspour, A., Jamialahmadi, T., Razi, B., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00686-6 · Cited by 5
Evolutionary history of MEK1 illuminates the nature of deleterious mutations
Andrianova, E. P., Marmion, R. A., Shvartsman, S. Y., & Zhulin, I. B. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304184120 · Cited by 5
Gylling, H. K., Öörni, K., Nylund, L., Wester, I., & Simonen, P. P. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.01.022 · Cited by 5
Genomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 5
Cholestérol alimentaire et morbi/mortalité cardiovasculaire
Hansel, B., & Giral, P. (2015) · OCL · doi:10.1051/ocl/2015001 · Cited by 5
Insights into blood lipids from rare variant discovery
Schmidt, E. M., & Willer, C. J. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.06.008 · Cited by 5
Current lipid-modifying agents
Agouridis, A. P., Filippatos, T. D., & Katsiki, N. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1035013 · Cited by 5
Should we consider ezetimibe to reach even lower LDL-C targets?
Agouridis, A. P., & Mikhailidis, D. P. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1005204 · Cited by 5
Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel
Bhatt, D. L. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv094 · Cited by 5
Holven, K. B., Ulven, S. M., & Bogsrud, M. P. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000646 · Cited by 5
Martín-Campos, J. M. (2021) · Biomedicines · doi:10.3390/biomedicines9111728 · Cited by 4
Metadata
- Authors
- The Myocardial Infarction Genetics Consortium Investigators
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- The Myocardial Infarction Genetics Consortium Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-27
- Volume
- 371
- Issue
- 22
- Pages
- 2072-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4335708
- OpenAlex
- W2478496979
- Cited by
- 419
- References
- 41
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 13 · 2023: 21 · 2022: 19 · 2021: 26 · 2020: 36 · 2019: 44 · 2018: 31 · 2017: 47 · 2016: 84 · 2015: 73 · 2014: 5
- FWCI
- 69.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- National Institutes of Health (UL1TR000124)
- Canadian Institutes of Health Research
- Medical Research Council (MR/L003120/1)
- National Institute on Aging (U01AG049505)
- National Heart, Lung, and Blood Institute (RC2HL102925, K08HL114642, RC2HL102926, R01HL107816, T32HL007208)
- National Human Genome Research Institute (U54HG003067, U01HG006378)
- National Cancer Institute (R01CA082659)
- National Institute of Nursing Research (R01NR013396)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK063491)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- NPC1L1, loss-of-function mutations, coronary artery disease, ezetimibe, LDL cholesterol, plasma lipids, genetic variants, therapeutic target, LDL cholesterol lowering
- MeSH terms
- Adult, Coronary Disease, Exons, Female, Genotype, Humans, Cholesterol, LDL, Male, Membrane Proteins, Middle Aged, Mutation, Protein Conformation, Risk, Triglycerides, Case-Control Studies, Sequence Analysis, DNA, Gene Silencing, Membrane Transport Proteins, Black People, White People, Asian People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
